Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that generic erosion will significantly stunt the growth of the bipolar disorder drug market in the United States. According to the new Pharmacor study entitled Bipolar Disorder, sales of anticonvulsants, antipsychotics, and antidepressants will begin a steady decline after 2008 as they lose patent protection.

"Although diagnosis rates for bipolar disorder are on the rise -- from 55% to 65% in the United States by 2013; from 40% to 50% in Europe by 2013; and from 40% to 50% in Japan by 2013 -- the drug market for the disorder will be hurt by generic erosion," said Anathea Waitekus, analyst at Decision Resources. "Generics erosion will significantly stunt growth potential, especially in the United States. Sales after 2008 will start to decline as the anticonvulsants, antipsychotics, and antidepressants lose patent protection. U.S. sales of antipsychotics, for example, will fall from $2.3 billion in 2008 to $1.5 billion in 2013."

About Bipolar Disorder

Bipolar disorder is a chronic and debilitating psychiatric illness characterized by recurrent episodes of mania, depression, or a mixture of both depression and mania. The disease suffers from a lack of accurate diagnosis and even when the illness is correctly diagnosed, treatment options for bipolar disorder remain unfavorable.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Dermatology Drug Market Will Experience Modest Growth of 8% Per Year Through 2008

View Now